BioXcel Therapeutics is trading at $0.13, down 5.77% in pre-market after its August 27, 2026 Chapter 11 filing and related restructuring developments.
- Secured up to $77.25 million in debtor-in-possession financing, including $19 million in new money and $58.25 million in rolled-up debt.
- Nasdaq notified the company of delisting, with trading suspension expected September 8, 2026.
- The broader market is only modestly weaker, leaving bankruptcy and delisting concerns as the primary catalyst.